2型糖尿病および糖尿病性腎症患者におけるフィネレノンの有効性および安全性

基本情報

NCT ID

NCT02540993

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

5,734

治験依頼者名

Bayer

概要

The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.

対象疾患

介入

依頼者（Sponsor）